Genetic analysis of nitric oxide synthase 1 variants in schizophrenia and bipolar disorder

American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics

Volumn 153, Issue 7, 2010, Pages 1318-1328

  Silberberg, Gilad ^a   Ben Shachar, Dorit ^b   Navon, Ruth ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Bipolar disorder; Dorsolateral prefrontal cortex (DLPFC); Gene expression; Nitric oxide synthase 1 (NOS1); Schizophrenia

Indexed keywords

ISOENZYME; NEURONAL NITRIC OXIDE SYNTHASE;

ALLELE; ARTICLE; BIPOLAR DISORDER; CLINICAL TRIAL; COMPUTER MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA ISOLATION; EXON; FLUORESCENCE ANALYSIS; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MAJOR CLINICAL STUDY; PREFRONTAL CORTEX; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RNA ISOLATION; SCHIZOPHRENIA;

BIPOLAR DISORDER; CASE-CONTROL STUDIES; GENETIC ASSOCIATION STUDIES; GENOTYPE; HUMANS; ISOENZYMES; NITRIC OXIDE SYNTHASE TYPE I; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC; SCHIZOPHRENIA; UP-REGULATION;

EID: 77957360809     PISSN: 15524841     EISSN: 1552485X     Source Type: Journal    
DOI: 10.1002/ajmg.b.31112     Document Type: Article

References (136)

1. Abdalla DS, Monteiro HP, Oliveira JA, Bechara EJ. 1986. Activities of superoxide dismutase and glutathione peroxidase in schizophrenic and manic-depressive patients. Clin Chem 32:805-807.
2. Adler CM, Holland SK, Schmithorst V, Tuchfarber MJ, Strakowski SM. 2004. Changes in neuronal activation in patients with bipolar disorder during performance of a working memory task. Bipolar Disord 6:540-549.
3. Akbarian S, Bunney WE Jr, Potkin SG, Wigal SB, Hagman JO, Sandman CA, Jones EG. 1993. Altered distribution of nicotinamide-adenine dinucleotide phosphate-diaphorase cells in frontal lobe of schizophrenics implies disturbances of cortical development. Arch Gen Psychiatry 50:169-177. (Pubitemid 23077471)
4. Akyol O, Zoroglu SS, Armutcu F, Sahin S, Gurel A. 2004. Nitric oxide as a physiopathological factor in neuropsychiatric disorders. In Vivo 18:377-390.
5. Alberini CM. 2005. Mechanisms of memory stabilization: Are consolidation and reconsolidation similar or distinct processes? Trends Neurosci 28:51-56.
6. Altshuler LL, Ventura J, van Gorp WG, Green MF, Theberge DC, Mintz J. 2004. Neurocognitive function in clinically stable men with bipolar I disorder or schizophrenia and normal control subjects. Biol Psychiatry 56:560-569.
7. Andreazza AC, Cassini C, Rosa AR, Leite MC, de Almeida LM, Nardin P, Cunha AB, Cereser KM, Santin A, Gottfried C, et al. 2007. Serum S100B and antioxidant enzymes in bipolar patients. J Psychiatr Res 41:523-529.
8. Andreazza AC, Kauer-Sant'anna M, Frey BN, Bond DJ, Kapczinski F, Young LT, Yatham LN. 2008. Oxidative stress markers in bipolar disorder: A meta-analysis. J Affect Disord 111:135-144.
9. Antunes F, Nunes C, Laranjinha J, Cadenas E. 2005. Redox interactions of nitric oxide with dopamine and its derivatives. Toxicology 208:207-212.
10. Arajarvi R, Suvisaari J, Suokas J, Schreck M, Haukka J, Hintikka J, Partonen T, Lonnqvist J. 2005. Prevalence and diagnosis of schizophrenia based on register, case record and interview data in an isolated Finnish birth cohort born 1940-1969. Soc Psychiatry Psychiatr Epidemiol 40:808-816.
11. Baba H, Suzuki T, Arai H, Emson PC. 2004. Expression of nNOS and soluble guanylate cyclase in schizophrenic brain. Neuroreport 15:677-680.
12. Badcock JC, Michiel PT, Rock D. 2005. Spatial working memory and planning ability: Contrasts between schizophrenia and bipolar I disorder. Cortex 41:753-763.
13. Barden N, Harvey M, Gagne B, Shink E, Tremblay M, Raymond C, Labbe M, Villeneuve A, Rochette D, Bordeleau L, et al. 2006. Analysis of single nucleotide polymorphisms in genes in the chromosome 12Q24.31 region points to P2RX7 as a susceptibility gene to bipolar affective disorder. Am J Med Genet Part B 141B:374-382.
14. Baxter LR Jr, Schwartz JM, Phelps ME, Mazziotta JC, Guze BH, Selin CE, Gerner RH, Sumida RM. 1989. Reduction of prefrontal cortex glucose metabolism common to three types of depression. Arch Gen Psychiatry 46:243-250.
15. Beneyto M, Meador-Woodruff JH. 2008. Lamina-specific abnormalities of NMDA receptor-associated postsynaptic protein transcripts in the prefrontal cortex in schizophrenia and bipolar disorder. Neuropsychopharmacology 33:2175-2186.
16. Bernstein HG, Stanarius A, Baumann B, Henning H, Krell D, Danos P, Falkai P, Bogerts B. 1998. Nitric oxide synthase-containing neurons in the human hypothalamus: Reduced number of immunoreactive cells in the paraventricular nucleus of depressive patients and schizophrenics. Neuroscience 83:867-875.
17. Bernstein HG, Krell D, Braunewell KH, Baumann B, Gundelfinger ED, Diekmann S, Danos P, Bogerts B. 2001. Increased number of nitric oxide synthase immunoreactive Purkinje cells and dentate nucleus neurons in schizophrenia. J Neurocytol 30:661-670.
18. Bernstein HG, Bogerts B, Keilhoff G. 2005a. The many faces of nitric oxide in schizophrenia. A review. Schizophr Res 78:69-86.
19. Bernstein HG, Heinemann A, Krell D, Dobrowolny H, Bielau H, Keilhoff G, Bogerts B. 2005b. Hypothalamic nitric oxide synthase in affective disorder: Focus on the suprachiasmatic nucleus. Cell Mol Biol (Noisy-le-grand) 51:279-284.
20. Berrettini W. 2003. Evidence for shared susceptibility in bipolar disorder and schizophrenia. Am J Med Genet Part C 123C:59-64. (Pubitemid 37356433)
21. Blumberg HP, Stern E, Ricketts S, Martinez D, de Asis J, White T, Epstein J, Isenberg N, McBride PA, Kemperman I, et al. 1999. Rostral and orbital prefrontal cortex dysfunction in the manic state of bipolar disorder. Am J Psychiatry 156:1986-1988.
22. Blumberg HP, Stern E, Martinez D, Ricketts S, de Asis J, White T, Epstein J, McBride PA, Eidelberg D, Kocsis JH, Silbersweig DA. 2000. Increased anterior cingulate and caudate activity in bipolar mania. Biol Psychiatry 48:1045-1052.
23. Blumberg HP, Leung HC, Skudlarski P, Lacadie CM, Fredericks CA, Harris BC, Charney DS, Gore JC, Krystal JH, Peterson BS. 2003. A functional magnetic resonance imaging study of bipolar disorder: State- and trait-related dysfunction in ventral prefrontal cortices. Arch Gen Psychiatry 60:601-609.
24. Boissel JP, Zelenka M, Godtel-Armbrust U, Feuerstein TJ, Forstermann U. 2003. Transcription of different exons 1 of the human neuronal nitric oxide synthase gene is dynamically regulated in a cell- and stimulus-specific manner. Biol Chem 384:351-362.
25. Boissel JP, Bros M, Schrock A, Godtel-Armbrust U, Forstermann U. 2004. Cyclic AMP-mediated upregulation of the expression of neuronal NO synthase in human A673 neuroepithelioma cells results in a decrease in the level of bioactive NO production: Analysis of the signaling mechanisms that are involved. Biochemistry 43:7197-7206.
26. Bredt DS, Snyder SH. 1992. Nitric oxide, a novel neuronal messenger. Neuron 8:3-11.
27. Brenman JE, Bredt DS. 1997. Synaptic signaling by nitric oxide. Curr Opin Neurobiol 7:374-378.
28. Bros M, Boissel JP, Godtel-Armbrust U, Forstermann U. 2006. Transcription of human neuronal nitric oxide synthase mRNAs derived from different first exons is partly controlled by exon 1-specific promoter sequences. Genomics 87:463-473.
29. Buckman TD, Kling AS, Eiduson S, Sutphin MS, Steinberg A. 1987. Glutathione peroxidase and CT scan abnormalities in schizophrenia. Biol Psychiatry 22:1349-1356.
30. Callicott JH, Mattay VS, Verchinski BA, Marenco S, Egan MF, Weinberger DR. 2003. Complexity of prefrontal cortical dysfunction in schizophrenia: More than up or down. Am J Psychiatry 160:2209-2215.
31. Cesena TI, Cardinaux JR, Kwok R, Schwartz J. 2007. CCAAT/enhancer-binding protein (C/EBP) beta is acetylated at multiple lysines: Acetylation of C/EBPbeta at lysine 39 modulates its ability to activate transcription. J Biol Chem 282:956-967.
32. Chang K, Adleman NE, Dienes K, Simeonova DI, Menon V, Reiss A. 2004. Anomalous prefrontal-subcortical activation in familial pediatric bipolar disorder: A functional magnetic resonance imaging investigation. Arch Gen Psychiatry 61:781-792.
33. Cook C. 1996. Neurologic and psychiatric treatment with inhibitors of brain nitric oxide synthase. U.S. Patent # 5,527,825. http//pharmalicensing.com/ licensing/displicopp/150.
34. Cote F, Laflamme L, Payet MD, Gallo-Payet N. 1998. Nitric oxide, a new second messenger involved in the action of angiotensin II on neuronal differentiation of NG108-1 cells. Endocr Res 24:403-407.
35. Das I, Khan NS, Puri BK, Sooranna SR, de Belleroche J, Hirsch SR. 1995. Elevated platelet calcium mobilization and nitric oxide synthase activity may reflect abnormalities in schizophrenic brain. Biochem Biophys Res Commun 212:375-380.
36. Dawson TM, Snyder SH. 1994. Gases as biological messengers: Nitric oxide and carbon monoxide in the brain. J Neurosci 14:5147-5159.
37. Dawson TM, Dawson VL, Snyder SH. 1992. A novel neuronal messenger molecule in brain: The free radical nitric oxide. Ann Neurol 32:297-311.
38. Dawson TM, Dawson VL, Snyder SH. 1994. Molecular mechanisms of nitric oxide actions in the brain. Ann N Y Acad Sci 738:76-85.
39. Dawson TM, Sasaki M, Gonzalez-Zulueta M, Dawson VL. 1998. Regulation of neuronal nitric oxide synthase and identification of novel nitric oxide signaling pathways. Prog Brain Res 118:3-11.
40. Del Bel EA, da Silva CA, Guimaraes FS, Bermudez-Echeverry M. 2004. Catalepsy induced by intra-striatal administration of nitric oxide synthase inhibitors in rats. Eur J Pharmacol 485:175-181.
41. Di Giacomo C, Sorrenti V, Salerno L, Cardile V, Guerrera F, Siracusa MA, Avitabile M, Vanella A. 2003. Novel inhibitors of neuronal nitric oxide synthase. Exp Biol Med (Maywood) 228:486-490.
42. Drevets WC, Price JL, Simpson JR Jr, Todd RD, Reich T, Vannier M, Raichle ME. 1997. Subgenual prefrontal cortex abnormalities in mood disorders. Nature 386:824-827.
43. Dumais N, Bounou S, Olivier M, Tremblay MJ. 2002. Prostaglandin E(2)-mediated activation of HIV-1 long terminal repeat transcription in human T cells necessitates CCAAT/enhancer binding protein (C/EBP) binding sites in addition to cooperative interactions between C/EBPbeta and cyclic adenosine 5′-monophosphate response element binding protein. J Immunol 168:274-282.
44. Ewald H, Degn B, Mors O, Kruse TA. 1998. Significant linkage between bipolar affective disorder and chromosome 12q24. Psychiatr Genet 8:131-140. (Pubitemid 28479008)
45. Fallin MD, Lasseter VK, Avramopoulos D, Nicodemus KK, Wolyniec PS, McGrath JA, Steel G, Nestadt G, Liang KY, Huganir RL, et al. 2005. Bipolar I disorder and schizophrenia: A 440-single-nucleotide polymorphism screen of 64 candidate genes among Ashkenazi Jewish case-parent trios. Am J Hum Genet 77:918-936.
46. Fossier P, Blanchard B, Ducrocq C, Leprince C, Tauc L, Baux G. 1999. Nitric oxide transforms serotonin into an inactive form and this affects neuromodulation. Neuroscience 93:597-603.
47. Galimberti D, Scarpini E, Venturelli E, Strobel A, Herterich S, Fenoglio C, Guidi I, Scalabrini D, Cortini F, Bresolin N, et al. 2008. Association of a NOS1 promoter repeat with Alzheimer's disease. Neurobiol Aging 29:1359-1365.
48. Garcia RA, Vasudevan K, Buonanno A. 2000. The neuregulin receptor ErbB-4 interacts with PDZ-containing proteins at neuronal synapses. Proc Natl Acad Sci USA 97:3596-3601.
49. Garthwaite J. 1991. Glutamate, nitric oxide and cell-cell signalling in the nervous system. Trends Neurosci 14:60-67.
50. Garthwaite J, Boulton CL. 1995. Nitric oxide signaling in the central nervous system. Annu Rev Physiol 57:683-706.
51. Glahn DC, Barrett J, Bearden CE, Mintz J, Green MF, Serap Monkul E, Najt P, Soares JC, Velligan DI. 2006. Dissociable mechanisms for memory impairment in bipolar disorder and schizophrenia. Psychol Med 36:1085-1095. (Pubitemid 44084012)
52. Gray JR, Braver TS, Raichle ME. 2002. Integration of emotion and cognition in the lateral prefrontal cortex. Proc Natl Acad Sci USA 99:4115-4120.
53. Griscavage JM, Fukuto JM, Komori Y, Ignarro LJ. 1994. Nitric oxide inhibits neuronal nitric oxide synthase by interacting with the heme prosthetic group. Role of tetrahydrobiopterin in modulating the inhibitory action of nitric oxide. J Biol Chem 269:21644-21649.
54. Gross SS, Wolin MS. 1995. Nitric oxide: Pathophysiological mechanisms. Annu Rev Physiol 57:737-769.
55. Hai T, Wolfgang CD, Marsee DK, Allen AE, Sivaprasad U. 1999. ATF3 and stress responses. Gene Expr 7:321-335.
56. Higgs BW, Elashoff M, Richman S, Barci B. 2006. An online database for brain disease research. BMC Genomics 7:70.
57. Hill SK, Harris MS, Herbener ES, Pavuluri M, Sweeney JA. 2008. Neurocognitive allied phenotypes for schizophrenia and bipolar disorder. Schizophr Bull 34:743-759.
58. Hirayasu Y, Shenton ME, Salisbury DF, Kwon JS, Wible CG, Fischer IA, Yurgelun-Todd D, Zarate C, Kikinis R, Jolesz FA, McCarley RW. 1999. Subgenual cingulate cortex volume in first-episode psychosis. Am J Psychiatry 156:1091-1093.
59. Holmans PA, Riley B, Pulver AE, Owen MJ, Wildenauer DB, Gejman PV, Mowry BJ, Laurent C, Kendler KS, Nestadt G, et al. 2009. Genomewide linkage scan of schizophrenia in a large multicenter pedigree sample using single nucleotide polymorphisms. Mol Psychiatry 14:786-795.
60. Holmes AJ, MacDonald A III, Carter CS, Barch DM, Andrew Stenger V, Cohen JD. 2005. Prefrontal functioning during context processing in schizophrenia and major depression: An event-related fMRI study. Schizophr Res 76:199-206.
61. Huang YZ, Won S, Ali DW, Wang Q, Tanowitz M, Du QS, Pelkey KA, Yang DJ, Xiong WC, Salter MW, Mei L. 2000. Regulation of neuregulin signaling by PSD-95 interacting with ErbB4 at CNS synapses. Neuron 26:443-455.
62. Izquierdo SA, Khan M. 2004. Hypnosis for schizophrenia. Cochrane Database Syst Rev, CD004160.
63. Karson CN, Griffin WS, Mrak RE, Husain M, Dawson TM, Snyder SH, Moore NC, Sturner WQ. 1996. Nitric oxide synthase (NOS) in schizophrenia: Increases in cerebellar vermis. Mol Chem Neuropathol 27:275-284.
64. Kerwin JF Jr, Lancaster JR Jr, Feldman PL. 1995. Nitric oxide: A new paradigm for second messengers. J Med Chem 38:4343-4362.
65. Kristiansen LV, Meador-Woodruff JH. 2005. Abnormal striatal expression of transcripts encoding NMDA interacting PSD proteins in schizophrenia, bipolar disorder and major depression. Schizophr Res 78:87-93.
66. Kristiansen LV, Beneyto M, Haroutunian V, Meador-Woodruff JH. 2006. Changes in NMDA receptor subunits and interacting PSD proteins in dorsolateral prefrontal and anterior cingulate cortex indicate abnormal regional expression in schizophrenia. Mol Psychiatry 11:737-747, 705.
67. Kuloglu M, Ustundag B, Atmaca M, Canatan H, Tezcan AE, Cinkilinc N. 2002. Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder. Cell Biochem Funct 20:171-175.
68. Laifenfeld D, Karry R, Klein E, Ben-Shachar D. 2005. Alterations in cell adhesion molecule L1 and functionally related genes in major depression: A postmortem study. Biol Psychiatry 57:716-725.
69. Larson ER, Shear PK, Krikorian R, Welge J, Strakowski SM. 2005. Working memoryand inhibitory controlamongmanic and euthymic patients with bipolar disorder. J Int Neuropsychol Soc 11:163-172.
70. Lawrence NS, Williams AM, Surguladze S, Giampietro V, Brammer MJ, Andrew C, Frangou S, Ecker C, Phillips ML. 2004. Subcortical and ventral prefrontal cortical neural responses to facial expressions distinguish patients with bipolar disorder and major depression. Biol Psychiatry 55:578-587.
71. Lewis DA. 2000. GABAergic local circuit neurons and prefrontal cortical dysfunction in schizophrenia. Brain Res Brain Res Rev 31:270-276.
72. Lewis DA, Gonzalez-Burgos G. 2000. Intrinsic excitatory connections in the prefrontal cortex and the pathophysiology of schizophrenia. Brain Res Bull 52:309-317.
73. Li HC, Chen QZ, Ma Y, Zhou JF. 2006. Imbalanced free radicals and antioxidant defense systems in schizophrenia: A comparative study. J Zhejiang Univ Sci B 7:981-986.
74. Lichtenstein P, Yip BH, Bjork C, Pawitan Y, Cannon TD, Sullivan PF, Hultman CM. 2009. Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: A population-based study. Lancet 373:234-239.
75. Livak KJ, Schmittgen TD. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods 25:402-408.
76. Machado-Vieira R, Andreazza AC, Viale CI, Zanatto V, Cereser V Jr, da Silva Vargas R, Kapczinski F, Portela LV, Souza DO, Salvador M, Gentil V. 2007. Oxidative stress parameters in unmedicated and treated bipolar subjects during initial manic episode: A possible role for lithium antioxidant effects. Neurosci Lett 421:33-36.
77. Mahadik SP, Mukherjee S. 1996. Free radical pathology and antioxidant defense in schizophrenia: A review. Schizophr Res 19:1-17.
78. Malhi GS, Lagopoulos J, Sachdev P, Mitchell PB, Ivanovski B, Parker GB. 2004a. Cognitive generation of affect in hypomania: An fMRI study. Bipolar Disord 6:271-285. (Pubitemid 39077087)
79. Malhi GS, Lagopoulos J, Ward PB, Kumari V, Mitchell PB, Parker GB, Ivanovski B, Sachdev P. 2004b. Cognitive generation of affect in bipolar depression: An fMRI study. Eur J Neurosci 19:741-754. (Pubitemid 38241313)
80. McCullumsmith RE, Kristiansen LV, Beneyto M, Scarr E, Dean B, Meador-Woodruff JH. 2007. Decreased NR1, NR2A, and SAP102 transcript expression in the hippocampus in bipolar disorder. Brain Res 1127:108-118.
81. McGrath J, Chapple B, Wright M. 2001. Working memoryin schizophrenia and mania: Correlation with symptoms during the acute and subacute phases. Acta Psychiatr Scand 103:181-188.
82. McGuffin P, Knight J, Breen G, Brewster S, Boyd PR, Craddock N, Gill M, Korszun A, Maier W, Middleton L, et al. 2005. Whole genome linkage scan of recurrent depressive disorder from the depression network study. Hum Mol Genet 14:3337-3345.
83. Meffert MK, Calakos NC, Scheller RH, Schulman H. 1996. Nitric oxide modulates synaptic vesicle docking fusion reactions. Neuron 16:1229-1236.
84. Merikangas KR, Akiskal HS, Angst J, Greenberg PE, Hirschfeld RM, Petukhova M, Kessler RC. 2007. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry 64:543-552.
85. Morissette J, Villeneuve A, Bordeleau L, Rochette D, Laberge C, Gagne B, Laprise C, Bouchard G, Plante M, Gobeil L, et al. 1999. Genome-wide search for linkage of bipolar affective disorders in a very large pedigree derived from a homogeneous population in Quebec points to a locus of major effect on chromosome 12q23-q24. Am J Med Genet 88:567-587.
86. Murray RM, Sham P, Van Os J, Zanelli J, Cannon M, McDonald C. 2004. A developmental model for similarities and dissimilarities between schizophrenia and bipolar disorder. Schizophr Res 71:405-416.
87. Nathan C, Xie QW. 1994. Nitric oxide synthases: Roles, tolls, and controls. Cell 78:915-918.
88. Ogawa H, Mizusawa A, Kikuchi Y, Hida W, Miki H, Shirato K. 1995. Nitric oxide as a retrograde messenger in the nucleus tractus solitarii of rats during hypoxia. J Physiol 486(Pt2): 495-504.
89. Okada D, Yap CC, Kojima H, Kikuchi K, Nagano T. 2004. Distinct glutamate receptors govern differential levels of nitric oxide production in a layer-specific manner in the rat cerebellar cortex. Neuroscience 125:461-472.
90. Owen MJ, Craddock N, O'Donovan MC. 2005. Schizophrenia: Genes at last? Trends Genet 21:518-525.
91. Pavuluri MN, O'Connor MM, Harral E, Sweeney JA. 2007. Affective neural circuitry during facial emotion processing in pediatric bipolar disorder. Biol Psychiatry 62:158-167. (Pubitemid 46963246)
92. Pogun S, Kuhar MJ. 1994. Regulation of neurotransmitter reuptake by nitric oxide. Ann N Y Acad Sci 738:305-315.
93. Pou SJ, Anderson DE, Surichamorn W, Keaton LL, Tod ML. 1994. Biological studies of a nitroso compound that releases nitric oxide upon illumination. Mol Pharmacol 46:709-715.
94. Prabakaran S, Swatton JE, Ryan MM, Huffaker SJ, Huang JT, Griffin JL, Wayland M, Freeman T, Dudbridge F, Lilley KS, et al. 2004. Mitochondrial dysfunction in schizophrenia: Evidence for compromised brain metabolism and oxidative stress. Mol Psychiatry 9:643, 684-697. (Pubitemid 38932173)
95. Rajkowska G, Selemon LD, Goldman-Rakic PS. 1998. Neuronal and glial somal size in the prefrontal cortex:Apostmortem morphometric study of schizophrenia and Huntington disease. Arch Gen Psychiatry 55:215-224.
96. Rajkowska G, Halaris A, Selemon LD. 2001. Reductions in neuronal and glial density characterize the dorsolateral prefrontal cortex in bipolar disorder. Biol Psychiatry 49:741-752.
97. Ramirez J, Garnica R, Boll MC, Montes S, Rios C. 2004. Low concentration of nitrite and nitrate in the cerebrospinal fluid from schizophrenic patients: A pilot study. Schizophr Res 68:357-361.
98. Ramji DP, Foka P. 2002. CCAAT/enhancer-binding proteins: Structure, function and regulation. Biochem J 365:561-575.
99. Ranjekar PK, Hinge A, Hegde MV, Ghate M, Kale A, Sitasawad S, Wagh UV, Debsikdar VB, Mahadik SP. 2003. Decreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patients. Psychiatry Res 121:109-122.
100. Reddy R, Keshavan M, Yao JK. 2003. Reduced plasma antioxidants in first-episode patients with schizophrenia. Schizophr Res 62:205-212.
101. Regenold WT, Phatak P, Marano CM, Gearhart L, Viens CH, Hisley KC. 2007. Myelin staining of deep white matter in the dorsolateral prefrontal cortex in schizophrenia, bipolar disorder, and unipolar major depression. Psychiatry Res 151:179-188.
102. Reif A, Herterich S, Strobel A, Ehlis AC, Saur D, Jacob CP, Wienker T, Topner T, Fritzen S, Walter U, et al. 2006. A neuronal nitric oxide synthase (NOS-I) haplotype associated with schizophrenia modifies prefrontal cortex function. Mol Psychiatry 11:286-300.
103. Reif A, Jacob CP, Rujescu D, Herterich S, Lang S, Gutknecht L, Baehne CG, Strobel A, Freitag CM, Giegling I, et al. 2009. Influence of functional variant of neuronal nitric oxide synthase on impulsive behaviors in humans. Arch Gen Psychiatry 66:41-50.
104. Rife T, Rasoul B, Pullen N, Mitchell D, Grathwol K, Kurth J. 2009. The effect of a promoter polymorphism on the transcription of nitric oxide synthase 1 and its relevance to Parkinson's disease. J Neurosci Res 87:2319-2325.
105. Ross HL, Nonnemacher MR, Hogan TH, Quiterio SJ, Henderson A, McAllister JJ, Krebs FC, Wigdahl B. 2001. Interaction between CCAAT/enhancer binding protein and cyclic AMP response element binding protein 1 regulates human immunodeficiency virus type 1 transcription in cells of the monocyte/macrophage lineage. J Virol 75:1842-1856.
106. Salerno L, Sorrenti V, Di Giacomo C, Romeo G, Siracusa MA. 2002. Progress in the development of selective nitric oxide synthase (NOS) inhibitors. Curr Pharm Des 8:177-200.
107. Saur D, Seidler B, Paehge H, Schusdziarra V, Allescher HD. 2002. Complex regulation of human neuronal nitric-oxide synthase exon 1c gene transcription. Essential role of Sp and ZNF family members of transcription factors. J Biol Chem 277:25798-25814.
108. Saur D, Vanderwinden JM, Seidler B, Schmid RM, De Laet MH, Allescher HD. 2004. Single-nucleotide promoter polymorphism alters transcription of neuronal nitric oxide synthase exon 1c in infantile hypertrophic pyloric stenosis. Proc Natl Acad Sci USA 101:1662-1667.
109. Savas HA, Gergerlioglu HS, Armutcu F, Herken H, Yilmaz HR, Kocoglu E, Selek S, Tutkun H, Zoroglu SS, Akyol O. 2006. Elevated serum nitric oxide and superoxide dismutase in euthymic bipolar patients: Impact of past episodes. World J Biol Psychiatry 7:51-55.
110. Schröck A, Boissel JP, Gödtel-Armbrust U, Förstermann U. 2001. Involvement of the cAMP transduction pathway in the regulation of the expression of the human neuronal nitric oxide synthase. Naunyn-Schmiedeb Arch Pharmacol R41:363.
111. Schuman EM, Madison DV. 1994. Nitric oxide and synaptic function. Annu Rev Neurosci 17:153-183.
112. Schumann C, Lenz G, Berghofer A, Muller-Oerlinghausen B. 1999. Non-adherence with long-term prophylaxis: A 6-year naturalistic follow-up study of affectively ill patients. Psychiatry Res 89:247-257.
113. Selek S, Savas HA, Gergerlioglu HS, Bulbul F, Uz E, Yumru M. 2008. The course of nitric oxide and superoxide dismutase during treatment of bipolar depressive episode. J Affect Disord 107:89-94.
114. Shinkai T, Ohmori O, Hori H, Nakamura J. 2002. Allelic association of the neuronal nitric oxide synthase (NOS1) gene with schizophrenia. Mol Psychiatry 7:560-563.
115. Silberberg G, Darvasi A, Pinkas-Kramarski R, Navon R. 2006. The involvement of ErbB4 with schizophrenia: Association and expression studies. Am J Med Genet Part B 141B:142-148.
116. Silberberg G, Levit A, Collier D, St Clair D, Munro J, Kerwin RW, Tondo L, Floris G, Breen G, Navon R. 2008. Stargazin involvement with bipolar disorder and response to lithium treatment. Pharmacogenet Genomics 18:403-412.
117. Silberberg G, Baruch K, Navon R. 2009. Detection of stable reference genes for real-time PCR analysis in schizophrenia and bipolar disorder. Anal Biochem 391:91-97.
118. Silva AJ, Elgersma Y, Costa RM. 2000. Molecular and cellular mechanisms of cognitive function: Implications for psychiatric disorders. Biol Psychiatry 47:200-209.
119. Skinner AO, Mahadik SP, Garver DL. 2005. Thiobarbituric acid reactive substances in the cerebrospinal fluid in schizophrenia. Schizophr Res 76:83-87.
120. Son H, Hawkins RD, Martin K, Kiebler M, Huang PL, Fishman MC, Kandel ER. 1996. Long-term potentiation is reduced in mice that are doubly mutant in endothelial and neuronal nitric oxide synthase. Cell 87:1015-1023.
121. Srivastava N, Barthwal MK, Dalal PK, Agarwal AK, Nag D, Srimal RC, Seth PK, Dikshit M. 2001. Nitrite content and antioxidant enzyme levels in the blood of schizophrenia patients. Psychopharmacology (Berl) 158:140-145. (Pubitemid 33020832)
122. Sweeney JA, Kmiec JA, Kupfer DJ. 2000. Neuropsychologic impairments in bipolar and unipolar mood disorders on the CANTAB neurocognitive battery. Biol Psychiatry 48:674-684.
123. Teasdale JD, Howard RJ, Cox SG, Ha Y, Brammer MJ, Williams SC, Checkley SA. 1999. Functional MRI study of the cognitive generation of affect. Am J Psychiatry 156:209-215.
124. Thaker G. 2008a. Psychosis endophenotypes in schizophrenia and bipolar disorder. Schizophr Bull 34:720-721. (Pubitemid 351957572)
125. Thaker GK. 2008b. Neurophysiological endophenotypes across bipolar and schizophrenia psychosis. Schizophr Bull 34:760-773.
126. Toro C, Deakin JF. 2005. NMDA receptor subunit NRI and postsynaptic protein PSD-95 in hippocampus and orbitofrontal cortex in schizophrenia and mood disorder. Schizophr Res 80:323-330.
127. Torrey EF, Webster M, Knable M, Johnston N, Yolken RH. 2000. The Stanley Foundation Brain Collection and Neuropathology Consortium. Schizophr Res 44:151-155.
128. Tsuang MT, Taylor L, Faraone SV. 2004. An overview of the genetics of psychotic mood disorders. J Psychiatr Res 38:3-15.
129. Varga M, Magnusson A, Flekkoy K, Ronneberg U, Opjordsmoen S. 2006. Insight, symptoms and neurocognition in bipolar I patients. J Affect Disord 91:1-9.
130. Wegener G, Volke V, Rosenberg R. 2000. Endogenous nitric oxide decreases hippocampal levels of serotonin and dopamine in vivo. Br J Pharmacol 130:575-580.
131. Xing G, Chavko M, Zhang LX, Yang S, Post RM. 2002. Decreased calcium-dependent constitutive nitric oxide synthase (cNOS) activity in prefrontal cortex in schizophrenia and depression. Schizophr Res 58:21-30.
132. Yanik M, Vural H, Kocyigit A, Tutkun H, Zoroglu SS, Herken H, Savas HA, Koylu A, Akyol O. 2003. Is the arginine-nitric oxide pathway involved in the pathogenesis of schizophrenia? Neuropsychobiology 47:61-65.
133. Yao JK, Reddy R, McElhinny LG, vanKammen DP. 1998. Reduced status of plasma total antioxidant capacity in schizophrenia. Schizophr Res 32:1-8.
134. Yao JK, Reddy R, van Kammen DP. 2000. Abnormal age-related changes of plasma antioxidant proteins in schizophrenia. Psychiatry Res 97:137-151.
135. Yao JK, Leonard S, Reddy RD. 2004. Increased nitric oxide radicals in postmortem brain from patients with schizophrenia. Schizophr Bull 30:923-934.
136. Yurgelun-Todd DA, Gruber SA, Kanayama G, Killgore WD, Baird AA, Young AD. 2000. fMRI during affect discrimination in bipolar affective disorder. Bipolar Disord 2:237-248.